# US 2018/0021260 A1 · Artificial Cell Constructs For Cellular Manipulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021260 A1
- Document ID: US20180021260A1
- Status: Published application
- Kind: A1
- Application number: 15/674,128
- Filed: 2017-08-10
- Published: 2018-01-25
- Earliest claimed: 2009-07-10
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education; Massachusetts Institute of Technology
- Applicants: University of Pittsburgh- Of the Commonwealth System of Higher Education; Massachusetts Institute of Technology
- Inventors: Steven R. Little
- Web page: https://patentgrep.com/patent/US20180021260A1

## CPC

- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1682: {Processes}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/2013: {IL-2}
- A61K 47/6921: {the form being a particulate, a powder, an adsorbate, a bead or a sphere}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- B01J 13/0065: {containing an organic phase}
- B01J 2208/00823: Mixing elements
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS

## Abstract

The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method, comprising:
a) providing,
i) a patient having received a tissue transplant, wherein said tissue is capable of immunological tolerance;
ii) an artificial particle comprising at least one soluble Treg cell factor and at least one surface bound Treg cell factor; and
b) administering said artificial particle to said patient under conditions such that said immunological tolerant state is induced in said tissue.

### Claim 24 (depends on 23)

The method of claim 23, wherein said artificial particle is porous.

### Claim 25 (depends on 23)

The method of claim 23, wherein said immunological tolerant state is not antigen-specific.

### Claim 26 (depends on 23)

The method of claim 23, wherein said artificial particle comprises compartments.

### Claim 27 (depends on 26)

The method of claim 26, wherein said compartments comprise said soluble factor.

### Claim 28 (depends on 23)

The method of claim 23, wherein said artificial particle is biodegradable, wherein said soluble factor undergoes controlled release.

### Claim 29 (depends on 28)

The method of claim 28, wherein said controlled release is a short term release.

### Claim 30 (depends on 29)

The method of claim 29, wherein said short term release is between 30 minutes 24 hours.

### Claim 31 (depends on 28)

The method of claim 28, wherein said controlled release is a long term release.

### Claim 32 (depends on 31)

The method of claim 31, wherein said long term release is between 24 hours-1 year.

### Claim 33 (depends on 31)

The method of claim 31, wherein said long term release is at least one year.

### Claim 34 (depends on 23)

The method of claim 23, wherein said immunological tissue tolerance is permanent.

### Claim at position 14

35-46. (canceled)
